Antibody (Suitable for clinical applications)
Specification | Recommendation |
---|---|
Recommended Dilution (Conc) | 1:50-1:200 |
Pretreatment | Citrate Buffer pH 6.0 |
Incubation Parameters | 30 min at Room Temperature |
Prior to use, inspect vial for the presence of any precipitate or other unusual physical properties. These can indicate that the antibody has degraded and is no longer suitable for patient samples. Please run positive and negative controls simultaneously with all patient samples to account and control for errors in laboratory procedure. Use of methods or materials not recommended by enQuire Bio including change to dilution range and detection system should be routinely validated by the user.
Cytokeratin 18 Information for Pathologists
Summary:
Molecular weight is 45 kDa. Pairs with CK8. Ethanol causes CK8/18+ Mallory body like inclusions by (a) causing oxidative stress, which (b) inhibits proteasomes that normally remove ubiquinated cytokeratins, which (c) causes accumulation of ubiquinated cytokeratins (Exp Mol Pathol 2006;81:191). Various CK8/CK18 mutations may increase susceptibility to liver disease (Gastroenterology 2005;129:885) including cryptogenic cirrhosis (J Clin Invest 1997;99:19). Is a marker of fetal mid-face (primary palate) growth and fusion (J Dent Res 2005;84:69).
Common Uses By Pathologists:
Serum tumor marker for breast cancer (Am J Clin Pathol 2005;123:66) and T3/T4 bladder carcinoma (Clin Biochem 2002;35:327). An airway epithelial cell autoantigen associated with nonallergic asthma; a possible serum marker (also CK19) for toluene diisocyanate-induced asthma among exposed workers (Yonsei Med J 2006;47:773). RT-PCR to assess sentinel lymph nodes in colon carcinoma (Scand J Gastroenterol 2006;41:1073) and lymph nodes of gastric carcinoma (World J Gastroenterol 2005;11:6530). Loss of expression in breast carcinoma may be a poor prognostic factor (Clin Cancer Res 2004;10:2670). Cleaved cytokeratin-18 is a marker of apoptosis (J Histochem Cytochem 2005;53:229).
Cytokeratin 18 General Information | |
---|---|
Alternate Names | |
Molecular Weight | |
48.1 kDa | |
Chromosomal Location | |
q13.13 [chr: 12] [chr_start: 52948871] [chr_end: 52952906] [strand: 1] | |
Curated Database and Bioinformatic Data | |
Gene Symbol | KRT18 |
Entrez Gene ID | 3875 |
RefSeq Protein Accession(s) | NP_000215; NP_954657 |
RefSeq mRNA Accession(s) | ; NM_199187; NM_000224 |
RefSeq Genomic Accession(s) | NC_000012; NG_008351; NG_008402 |
UniProt ID(s) | P05783 |
PharmGKB ID(s) | PA30217 |
KEGG Gene ID(s) | hsa:3875 |
Associated Diseases (KEGG IDs) | Cirrhosis (CIRRH) [MIM:215600]: A liver disease characterized by severe panlobular liver-cell swelling with Mallory body formation, prominent pericellular fibrosis, and marked deposits of copper. Clinical features include abdomen swelling, jaundice and pulmonary hypertension. {ECO:0000269|PubMed:12724528, ECO:0000269|PubMed:9011570}. The disease is caused by mutations affecting the gene represented in this entry. |
General Description of Cytokeratin 18 . | |
This antibody is specific to human cytokeratin 18 of 45 kDa. Cytokeratin 18 belongs to a family of acidic type A keratins and exists along with cytokeratin 8 in most simple ductal and glandular epithelia. This antibody does not react with squamous epithelium. It reacts with benign and malignant epithelial lesions as well as a majority of adenocarcinomas and basal cell carcinomas. |
There are no reviews yet.